Anti-myeloma effect of homoharringtonine with concomitant targeting of the myeloma-promoting molecules, Mcl-1, XIAP, and beta-catenin (Q39991473)

16 September 2017

title

Anti-myeloma effect of homoharringtonine with concomitant targeting of the myeloma-promoting molecules, Mcl-1, XIAP, and beta-catenin (English)

1 reference

16 September 2017

11

Michael Andreeff

1 reference

16 September 2017

Junya Kuroda

1

1 reference

16 September 2017

Yuri Kamitsuji

2

1 reference

16 September 2017

Shinya Kimura

3

1 reference

16 September 2017

Eishi Ashihara

4

1 reference

16 September 2017

Eri Kawata

5

1 reference

16 September 2017

Yoko Nakagawa

6

1 reference

16 September 2017

Miki Takeuichi

7

1 reference

16 September 2017

Yoshihide Murotani

8

1 reference

16 September 2017

Asumi Yokota

9

1 reference

16 September 2017

Ruriko Tanaka

10

1 reference

16 September 2017

Masafumi Taniwaki

12

1 reference

16 September 2017

Taira Maekawa

13

1 reference

16 September 2017

publication date

17 April 2008

1 reference

International Journal of Hematology

16 September 2017

language of work or name

English

0 references

published in

1 reference

16 September 2017

volume

87

1 reference

16 September 2017

issue

5

1 reference

16 September 2017

page(s)

507-515

1 reference

Multistep Tumorigenesis of Multiple Myeloma: Its Molecular Delineation

16 September 2017

cites work

1 reference

12 December 2020

VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosis

1 reference

12 December 2020

Frequent occurrence of CCND1 deregulation in patients with early stages of plasma cell dyscrasia

1 reference

12 December 2020

A pooled analysis of karyotypic patterns, breakpoints and imbalances in 783 cytogenetically abnormal multiple myelomas reveals frequently involved chromosome segments as well as significant age- and sex-related differences

1 reference

12 December 2020

Myeloma cell-osteoclast interaction enhances angiogenesis together with bone resorption: a role for vascular endothelial cell growth factor and osteopontin

1 reference

12 December 2020

Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics

1 reference

12 December 2020

BH3-only proteins in cell death initiation, malignant disease and anticancer therapy.

1 reference

12 December 2020

NBK/BIK antagonizes MCL-1 and BCL-XL and activates BAK-mediated apoptosis in response to protein synthesis inhibition

1 reference

12 December 2020

Rapid turnover of mcl-1 couples translation to cell survival and apoptosis

1 reference

12 December 2020

Homoharringtonine induces apoptosis and growth arrest in human myeloma cells

1 reference

12 December 2020

The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim.

1 reference

12 December 2020

The imbalance between Bim and Mcl-1 expression controls the survival of human myeloma cells

1 reference

12 December 2020

Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia

1 reference

12 December 2020

The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma

1 reference

12 December 2020

Illegitimate WNT signaling promotes proliferation of multiple myeloma cells

1 reference

12 December 2020

Substrate cleavage by caspases generates protein fragments with Smac/Diablo-like activities

1 reference

12 December 2020

Semisynthetic homoharringtonine induces apoptosis via inhibition of protein synthesis and triggers rapid myeloid cell leukemia-1 down-regulation in myeloid leukemia cells

1 reference

12 December 2020

Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli

1 reference

12 December 2020

The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph+ leukemia activity of imatinib mesylate

1 reference

12 December 2020

Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function

1 reference

12 December 2020

1 reference

12 December 2020

Apoptotic response to homoharringtonine in human wt p53 leukemic cells is independent of reactive oxygen species generation and implicates Bax translocation, mitochondrial cytochrome c release and caspase activation

1 reference

12 December 2020

Alkaloid homoharringtonine inhibits polypeptide chain elongation on human ribosomes on the step of peptide bond formation

1 reference

12 December 2020

Myeloid cell factor-1 is a critical survival factor for multiple myeloma

1 reference

12 December 2020

Melphalan-induced apoptosis in multiple myeloma cells is associated with a cleavage of Mcl-1 and Bim and a decrease in the Mcl-1/Bim complex

1 reference

12 December 2020

State of the art therapy in multiple myeloma and future perspectives

1 reference

12 December 2020

Multiple myeloma: clinical features and indications for therapy

1 reference

12 December 2020

Activation of N-ras and K-ras induced by interleukin-6 in a myeloma cell line: implications for disease progression and therapeutic response

1 reference

12 December 2020

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

1 reference

12 December 2020

Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion

1 reference

12 December 2020

The BH3-Only Protein Bid Is Dispensable for DNA Damage- and Replicative Stress-Induced Apoptosis or Cell-Cycle Arrest

1 reference

12 December 2020

Targeting the beta-catenin/TCF transcriptional complex in the treatment of multiple myeloma.

1 reference

12 December 2020

Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma

1 reference

12 December 2020

A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma

1 reference

12 December 2020

β-catenin is a target for the ubiquitin–proteasome pathway

1 reference

12 December 2020

Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation

1 reference

12 December 2020

Cleavage of Mcl-1 by caspases impaired its ability to counteract Bim-induced apoptosis.

1 reference

12 December 2020

IAP family protein expression correlates with poor outcome of multiple myeloma patients in association with chemotherapy-induced overexpression of multidrug resistance genes

1 reference

12 December 2020

The Bcl2 family: regulators of the cellular life-or-death switch

1 reference

12 December 2020

Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival.

1 reference

12 December 2020

Homoharringtonine: history, current research, and future direction

1 reference

12 December 2020

Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic.

1 reference

12 December 2020

Proteolytic processing of the adherens junctions components beta-catenin and gamma-catenin/plakoglobin during apoptosis

1 reference

12 December 2020

Refractory multiple myeloma treated with homoharringtonine: report of two cases

1 reference

12 December 2020

ABT-737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug-resistance mechanisms

1 reference

12 December 2020

An inhibitor of Bcl-2 family proteins induces regression of solid tumours

1 reference

12 December 2020

A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma

1 reference

12 December 2020

MCL-1 expression in B-cell non-Hodgkin's lymphomas

1 reference

12 December 2020

Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets

1 reference

12 December 2020

The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions

1 reference

12 December 2020

10.1007/S12185-008-0081-8

Identifiers

DOI

1 reference

16 September 2017

1 reference